Contract Backlog Expands to C$2.5M, FDA CPIM Completed, Nature Portfolio Study Accepted, Major Channel Partner Onboarding, and CAMH Research Award SecuredTORONTO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered precision analytics in the pharmaceutical industry, today provided a business update highlighting significant progre ...

TORONTO, Dec. 15, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered precision analytics in the pharmaceutical industry, today announced the completion of its Critical Path Innovation Meeting (CPIM) with the U.S. Food and Drug Administration (FDA). During this scientific exchange, FDA provided feedback on NetraAI—NetraMark's explainable ...

Core Points - The company is excited to share recent announcements made on their Investor Relations website [2] - The presentation includes key executives such as the CEO, CFO, and COO, indicating a strong leadership presence [1] - Forward-looking statements will be made during the discussion, highlighting the company's focus on future growth and developments [3]

Core Viewpoint - EnWave Corporation will report its financial results for Q4 2025 and the fiscal year ending September 30, 2025, on December 15, 2025, before market opening [1] Group 1: Financial Results Announcement - The financial statements and Management Discussion and Analysis (MD&A) will be available on SEDAR and the company's website [1] - A conference call is scheduled for December 15, 2025, at 7:00 a.m. Pacific Time to discuss the results and business outlook [2][3] Group 2: Company Overview - EnWave is a leader in vacuum microwave dehydration technology, with a strong intellectual property portfolio and a proven drying solution for food, pharmaceutical, and cannabis industries [4] - The company has over fifty partners across twenty-four countries, utilizing its technology to create innovative snacks and improve existing products [5] Group 3: Business Strategy - EnWave's strategy focuses on signing royalty-bearing commercial licenses with food producers to enhance drying efficiency compared to traditional methods [6]

Core Insights - NetraMark Holdings Inc. is participating in the 45th Annual Growth Conference hosted by Canaccord Genuity from August 12-14, 2025, in Boston, Massachusetts, where CEO George Achilleos will engage with institutional investors and strategic partners [1][2][4] Company Overview - NetraMark is focused on transforming clinical development through its AI platform, NetraAI, which extracts clinically relevant insights from complex datasets to identify patient subpopulations, mitigate placebo effects, and improve patient selection strategies [3][5] - The company's technology utilizes a novel topology-based algorithm that allows for effective segmentation of patient data, enabling the application of various machine learning methods to enhance drug response analysis and treatment efficacy [5] Conference Participation - The conference serves as a networking venue for innovative growth companies and institutional investors, providing opportunities for strategic collaboration and showcasing new technology platforms [2] - George Achilleos will be available for one-on-one meetings to discuss the application of NetraMark's AI platform across therapeutic areas and its role in supporting precision medicine strategies [4]

Core Insights - NetraMark Holdings Inc. is participating in the 45th Annual Growth Conference hosted by Canaccord Genuity from August 12-14, 2025, in Boston, Massachusetts, where CEO George Achilleos will engage with institutional investors and strategic partners [1][2][4] Company Overview - NetraMark is focused on transforming clinical development through its AI platform, NetraAI, which extracts clinically relevant insights from complex datasets to identify patient subpopulations, mitigate placebo effects, and improve patient selection strategies [3][5] - The company's technology allows for the segmentation of diseases and classification of patients based on their sensitivity to drugs and treatment efficacy, utilizing a novel topology-based algorithm [5] Conference Participation - The conference serves as a networking venue for innovative growth companies and institutional investors, providing opportunities for strategic collaboration and showcasing new technology platforms [2] - George Achilleos will be available for one-on-one meetings to discuss the application of NetraMark's AI platform across various therapeutic areas [4]